Alroy Erez 4
4 · Nano-X Imaging Ltd. · Filed Jun 15, 2026
Research Summary
AI-generated summary of this filing
Nano-X (NNOX) Director Alroy Erez Sells 678 Shares
What Happened
Alroy Erez, a director of Nano-X Imaging Ltd. (NNOX), reported two sales on June 10, 2026 totaling 678 ordinary shares disposed at $1.65 per share for aggregate proceeds of $1,119. According to the filing, these shares were sold to cover tax liabilities arising from the vesting of restricted share units (RSUs).
Key Details
- Transaction date: June 10, 2026; Price: $1.65 per share; Total shares sold: 209 and 469 (678 total); Total proceeds: $345 and $774 (≈ $1,119).
- Transaction type: Sale (reported as open market or private sale); footnote indicates sale was for tax withholding on RSU vesting.
- Holdings reported in footnotes: 6,753 ordinary shares remain under one RSU grant and 17,075 ordinary shares remain under a second RSU grant (total 23,828 remaining under those two grants, as disclosed).
- Option/vesting notes: Options from grants on Dec 28, 2022 vest fully by June 30, 2026; options from Dec 31, 2023 vest fully by Aug 14, 2027 (vesting schedules noted in filing).
- Filing date: June 15, 2026 for transactions on June 10, 2026 (filed five days after the trades).
Context
Footnotes state the shares sold were tied to the settlement/withholding for RSU vesting (routine tax-related sales), and the filing also lists remaining RSU and option vesting schedules. Tax-withholding sales are common and are generally administrative rather than a directional bet on the company.
Insider Transaction Report
Form 4
Alroy Erez
Director
Transactions
- Sale
Ordinary Shares
[F1][F2]2026-06-10$1.65/sh−209$345→ 6,753 total - Sale
Ordinary Shares
[F1][F3]2026-06-10$1.65/sh−469$774→ 17,075 total
Holdings
- 50,000
Stock Option (right to buy ordinary shares)
[F4][F5]Exercise: $17.63Exp: 2032-12-28→ Ordinary Shares (50,000 underlying) - 10,000
Stock Option (right to buy ordinary shares)
[F4][F6]Exercise: $11.52Exp: 2033-12-31→ Ordinary Shares (10,000 underlying)
Footnotes (6)
- [F1]The transaction reported in this row involved the sale of ordinary shares to cover tax liabilities arising from the vesting of restricted share units ("RSUs").
- [F2]The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer that began vesting on December 10, 2024. Currently, 6,753 ordinary shares constitute the remainder of the ordinary shares held by, or issuable to, the Reporting Person under the subject grant. The 7,792 RSUs originally granted vest (and settle for underlying ordinary shares) on an equal, quarterly basis over twelve calendar quarters (for 649.33 underlying ordinary shares per quarter) such that all such 7,792 RSUs - reduced by RSUs for which underlying shares have been sold to cover tax liability - will be vested by December 10, 2027.
- [F3]The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer that began vesting on December 10, 2025. Currently, 17,075 ordinary shares constitute the remainder of the ordinary shares held by, or issuable to, the Reporting Person under the subject grant. The 17,544 RSUs originally granted vest (and settle for underlying ordinary shares) on an equal, quarterly basis over twelve calendar quarters (for 1,462 underlying ordinary shares per quarter) such that all such 17,544 RSUs - reduced by RSUs for which underlying shares have been sold to cover tax liability - will be vested by December 10, 2028.
- [F4]There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
- [F5]The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the date of appointment of the Reporting Person to the Issuer's Board of Directors on June 30, 2022, such that all options reported in this row will be exercisable by the four-year anniversary of that appointment date (June 30, 2026).
- [F6]The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable by the four-year anniversary of that grant approval date (August 14, 2027).
Signature
/s/ Marina Gofman Feler, attorney-in-fact|2026-06-15